Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bemiparin→

Bemiparin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9041-08-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Low-molecular-weight heparin (LMWH)indirect anticoagulant
Mechanism of action
Binds antithrombin and potentiates its inhibition of activated factor Xa, with a smaller effect on thrombin (factor IIa), thereby reducing thrombin generation and fibrin clot formation.
Indications / reported uses
  • Prevention of venous thromboembolic events in patients undergoing selected surgical procedures or immobilisation, according to local product authorisation
  • Treatment of established deep-vein thrombosis in selected jurisdictions and formulations; dose and duration are product-specific

Sources: NLM MeSH — Bemiparin · PubMed — Bemiparin pharmacology and clinical use · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Low-molecular-weight heparin (LMWH); indirect anticoagulant

Mechanism of action

Binds antithrombin and potentiates its inhibition of activated factor Xa, with a smaller effect on thrombin (factor IIa), thereby reducing thrombin generation and fibrin clot formation.

General use cases

  • Prevention of venous thromboembolic events in patients undergoing selected surgical procedures or immobilisation, according to local product authorisation
  • Treatment of established deep-vein thrombosis in selected jurisdictions and formulations; dose and duration are product-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Bemiparin Environmental Risk Assessment (ERA) (the Bemiparin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.